本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
HONG KONG, Dec. 7, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the successful inclusion of all five of the Company's self-developed innovative drugs into the updated National Reimbursement Drug List (NRDL) for 2025, released by China's National Healthcare Security Administration (NHSA), effective January 1, 2026. These inclusions cover both newly added indications of previously included drugs, and as well as those participating in national reimbursement negotiations for the first time. With these inclusions, all approved indications for Akeso's five independently commercialized, internally developed drugs are now part of the NRDL. Dr. Yu Xia, Founder, Chairwoman, President, and CEO of Akeso, said: "We are truly delighted to witness that all approved indications of the company's five self-developed innovative drugs have been successfully included in the National Reimbursement Drug List (NRDL). The inclusion of these drugs—which address major tumor diseases with the highest incidence rates in China, such as lung cancer, gastric cancer, cervical cancer, and nasopharyngeal cancer, as well as metabolic and autoimmune disorders like hypercholesterolemia and psoriasis—enables Chinese patients to be among the first in the world to benefit from optimal treatment options. This achievement reduces the financial burden on patients and provides superior alternatives for tackling significant public health challenges. Notably, even prior to their inclusion in the NRDL, these drugs had already gained extensive and profound recognition from hospitals, physicians, and patients in real-world clinical practice, thanks to their breakthrough clinical value. The successful entry of multiple indications of these five products into the NRDL will further enhance end-users' awareness and trust in the company's innovative drugs, lay a solid foundation for accelerating their broader clinical adoption, propel Akeso's commercialization of innovative drugs into a phase of sustained, rapid, and high-quality development, and strengthen the groundwork for the company's deepened global expansion. Akeso remains patient-centric and clinical value-driven, committed to developing more breakthrough therapies so that patients worldwide can benefit from novel treatments. This has always been the original intent of our drug innovation, and it is what we take pride in." Ivonescimab: All 1L and 2L NSCLC Indications Now Covered by NRDL Akeso's first-in-class PD-1/VEGF bispecific antibody, ivonescimab, has successfully secured the inclusion of its new first-line indication for PD-L1-positive non-small cell lung cancer (NSCLC) in the NRDL. In a Phase III head-to-head clinical trial, ivonescimab demonstrated compelling results, reducing the risk of disease progression or death by 49% compared to pembrolizumab. Notably, ivonescimab is the first drug globally to show significantly superior efficacy over pembrolizumab in a Phase III trial. This breakthrough clinical value has been widely recognized by global academic and biopharma communities, as well as expert evaluators during this year's NRDL negotiation. Ivonescimab for the treatment of EGFR-TKI resistant NSCLC was already included in the NRDL in 2024. Cadonilimab: All 1L Gastric Cancer, 1L Cervical Cancer, and 2L/3L Cervical Cancer Indications Now Covered by NRDL Akeso's first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, has successfully negotiated the inclusion of its new first-line gastric cancer and first-line cervical cancer indications into the NRDL. Cadonilimab is the only immuno-oncology drug globally to demonstrate significant clinical benefits in first-line gastric cancer and first-line cervical cancer across all patient populations (regardless of PD-L1 expression), representing breakthrough therapeutic value. Cadonilimab for the treatment of recurrent or metastatic cervical cancer was already included in the NRDL in 2024. Penpulimab: All 4 Approved Indications Now Covered by NRDL Penpulimab, a differentiated PD-1 monoclonal antibody, participated in the national reimbursement negotiation for the first time in 2025. Two of its indications—first-line and ≥2L treatment of nasopharyngeal carcinoma (NPC)—have already been approved by the U.S. FDA. During this negotiation, penpulimab successfully secured NRDL inclusion for all four of its approved indications: first-line treatment of squamous NSCLC, first-line treatment of NPC, ≥3L treatment of NPC, and ≥3L treatment of relapsed/refractory classical Hodgkin lymphoma (R/R cHL). Ebdarokimab (IL-12/IL-23): Psoriasis Indication Now Covered by NRDL Ebdarokimab is China's first independently developed innovative drug targeting IL-12/IL-23, and the first approved drug from Akeso in the field of autoimmune diseases. Ebdarokimab participated in the national reimbursement negotiation for the first time in 2025, and its indication for the treatment of moderate-to-severe psoriasis was successfully negotiated and included in the NRDL. Ebronucimab (PCSK9): Both Approved Indications for Hypercholesterolemia Now Covered by NRDL Ebronucimab participated in the national reimbursement negotiation for the first time in 2025. The two approved indications of ebronucimab, the treatment of primary hypercholesterolemia and mixed dyslipidemia, and heterozygous familial hypercholesterolemia, were both successfully negotiated and included in the NRDL. Forward-Looking Statement of Akeso, Inc. This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. About Akeso Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 26 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.
成都2025年12月7日 /美通社/ -- 12月7日，國家醫療保障局、人力資源社會保障部公佈了《國家基本醫療保險、生育保險和工傷保險藥品目錄及商業健康保險創新藥品目錄（2025年）》，科倫博泰三款新藥首次成功入選國家基本醫保目錄，分別是蘆康沙妥珠單抗(佳泰萊®)、西妥昔單抗N01（達泰萊®）和塔戈利單抗（科泰萊®）。新版醫保目錄將於2026年1月1日起正式實施。 蘆康沙妥珠單抗是科倫博泰自主研發的一款新型TROP2 ADC，於2024年11月獲批上市，用於治療既往至少接受過2種系統治療（其中至少1種治療針對晚期或轉移性階段）的不可切除的局部晚期或轉移性三陰性乳腺癌（TNBC），成為首個獲得完全批准上市的國產ADC藥物。2025年3月，其第二項新增適應症獲批上市，用於治療經表皮生長因數受體酪氨酸激酶抑制劑（EGFR-TKI）和含鉑化療治療後進展的EGFR突變陽性的局部晚期或轉移性非鱗狀非小細胞肺癌（NSCLC），這也讓其成為全球首個在肺癌適應症上獲批的TROP2 ADC。此次國家基本醫保目錄公佈，蘆康沙妥珠單抗的兩項適應症均被成功納入。 蘆康沙妥珠單抗單藥治療二線及以上晚期TNBC的關鍵III期臨床研究資料顯示：（１）無進展生存期（PFS）方面，截至2023年6月21日，蘆康沙妥珠單抗的中位PFS為5.7個月，相比化療顯著延長，疾病進展或死亡風險顯著降低69%；（２）總生存期（OS）方面，截至2023年11月30日（下同），蘆康沙妥珠單抗的中位OS為14.3個月，相比化療死亡風險顯著降低47%；（３）在腫瘤緩解方面，蘆康沙妥珠單抗相比化療可達到更高的客觀緩解率（ORR）（46.1% vs 12.3%），中位緩解持續時間（DoR）也更長（7.1個月vs 3.0個月）；（４）安全性方面，蘆康沙妥珠單抗治療TNBC的整體安全性可管可控，最常見治療相關不良事件（TRAEs）為血液學毒性。 蘆康沙妥珠單抗單藥對比多西他賽治療三線EGFR突變NSCLC的關鍵臨床研究資料顯示：（１）截至2024年6月6日，BIRC評估的中位PFS為6.2個月vs 2.8個月，HR=0.27；截至2024年12月31日，INV評估的中位PFS為7.9個月vs 2.8個月，HR=0.23；（２）截至2024年12月31日，兩組的中位OS均尚未達到，蘆康沙妥珠單抗組發生死亡的風險降低51%，顯示出統計學的顯著改善。對於因交叉給藥而調整的中位OS，採用秩保持結構失效時間（RPSFT）模型分析，多西他賽組為9.3個月，蘆康沙妥珠單抗組尚未達到，與多西他賽相比發生死亡的風險降低64%；（３）截至2024年6月6日，BIRC評估的確認ORR為41.8% vs 15.6%;（４）安全性方面，蘆康沙妥珠單抗組未發現新的安全性信號，與既往報導一致，兩組最常見的治療相關不良事件均為血液學毒性，但蘆康沙妥珠單抗組≥3級TRAE和嚴重TRAE發生率低於多西他賽組，且未發生間質性肺炎（ILD）。 西妥昔單抗N01是一種重組抗EGFR人鼠嵌合單克隆抗體，可以抑制EGFR表達的腫瘤細胞的生長和存活。2025年2月，西妥昔單抗N01與FOLFOX或FOLFIRI方案聯合用於一線治療RAS基因野生型的轉移性結直腸癌獲批上市。該項適應症的獲批是基於一項與西妥昔單抗注射液（愛必妥®）聯合化療進行頭對頭對照的大樣本III期臨床研究，證明了西妥昔單抗N01與原研具有臨床等效性。臨床研究資料顯示：（１）西妥昔單抗N01聯合化療在ORR方面具有臨床等效性，西妥昔單抗N01 vs西妥昔單抗注射液(愛必妥®):71.0% vs 77.5%，ORR率比為0.93；（２）西妥昔單抗N01在DoR和PFS方面與西妥昔單抗注射液(愛必妥®)相比未顯示有臨床和統計學意義的差異（中位PFS：10.9個月vs 10.8個月，HR=1.03；中位DoR：10.2個月vs 9.5個月）；（３）安全性方面，研究已充分證明西妥昔單抗N01聯合化療在安全性、耐受性和免疫原性方面與西妥昔單抗注射液(愛必妥®)聯合化療相當。 塔戈利單抗是一種靶向PD-L1的人源化單抗，作為科倫博泰免疫療法的支柱，於2024年12月獲批上市，適應症為既往接受過二線及以上化療失敗的復發或轉移性（R/M）鼻咽癌（NPC）；2025年1月，其聯合順鉑和吉西他濱用於一線治療R/M NPC的第二項適應症獲批上市，是全球首個獲批一線治療NPC的PD-L1單抗。上述兩項適應症均被納入2025年版國家基本醫保目錄。 塔戈利單抗單藥在經二線及以上治療的R/M NPC患者中展現出了良好的療效與安全性，研究結果顯示：截至2022年1月13日，塔戈利單抗單藥治療的ORR為26.5%，中位PFS為2.8個月，中位OS為15.3個月，並且患者整體安全性良好、可控。KL167-Ⅲ-08研究進一步驗證了其在R/M NPC患者一線治療中的臨床應用價值，研究結果顯示：（１）截至2024年2月4日，與化療相比，塔戈利單抗聯合順鉑和吉西他濱一線治療復發或轉移性鼻咽癌可獲得更優的PFS、更高的ORR和更長的DoR，且無論患者PD-L1表達如何，均可獲益；（２）塔戈利單抗聯合化療組的中位PFS未達到，安慰劑聯合化療中位PFS為7.9個月，疾病進展或死亡風險降低了53%；（３）在腫瘤緩解方面，ORR為81.7% vs74.5%；中位DoR為11.7個月 vs 5.8個月，HR=0.48，比安慰劑組延長近1倍;（４）已觀察到塔戈利單抗聯合化療OS的獲益趨勢，其死亡風險降低了38%。 科倫博泰首席執行官葛均友表示：「非常高興公司的三款產品順利納入國家基本醫保目錄，這是公司創新成果轉化為患者可及的健康福祉的重要舉措。2025年國家醫保藥品目錄納入了一些彌補基本醫保保障空白的藥品，如三陰性乳腺癌、肺癌等重大疾病用藥，我們充分感受到國家醫保局對中國創新藥的支持鼓勵，對增進民生福祉的高度重視，以及對科倫博泰創新能力的肯定。公司將始終秉承『以博愛之心，事民眾安泰之業』的理念，潛心研製更多新藥、好藥，同時積極回應國家醫藥政策，讓中國創新藥的溫度，傳遞到每一位元需要的患者手中，助力健康中國。」 關於蘆康沙妥珠單抗(sac-TMT)(佳泰萊®) 作為本公司的核心產品，蘆康沙妥珠單抗(sac-TMT)是一款本公司擁有自主智慧財產權的新型TROP2 ADC，針對非小細胞肺癌（NSCLC）、乳腺癌（BC）、胃癌（GC）、婦科腫瘤等晚期實體瘤。蘆康沙妥珠單抗(sac-TMT)採用新型連接子進行開發，其通過偶聯一種貝洛替康衍生的拓撲異構酶I抑制劑作為有效載荷，藥物抗體比(DAR)達到7.4。蘆康沙妥珠單抗(sac-TMT)通過重組抗TROP2人源化單克隆抗體特異性識別腫瘤細胞表面的TROP2，其後被腫瘤細胞內吞併於細胞內釋放有效載荷KL610023。KL610023作為拓撲異構酶I抑制劑，可誘導腫瘤細胞DNA損傷，進而導致細胞週期阻滯及細胞凋亡。此外，其亦於腫瘤微環境中釋放KL610023。鑒於KL610023具有細胞膜滲透性，其可實現旁觀者效應，即殺死鄰近的腫瘤細胞。 於2022年5月，本公司授予默沙東(美國新澤西州羅威市默克公司的商號)在大中華區(包括中國內地、香港、澳門及臺灣)以外的所有地區開發、使用、製造及商業化蘆康沙妥珠單抗(sac-TMT)的獨家權利。 截止目前，蘆康沙妥珠單抗(sac-TMT)的3項適應症已於中國獲批上市，分別用於治療既往至少接受過2種系統治療(其中至少1種治療針對晚期或轉移性階段)的不可切除的局部晚期或轉移性三陰性乳腺癌(TNBC)、經EGFR-TKI和含鉑化療治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC以及經EGFR-TKI治療後進展的EGFR基因突變陽性的局部晚期或轉移性非鱗狀NSCLC。蘆康沙妥珠單抗(sac-TMT)是全球首個在肺癌適應症獲批上市的TROP2 ADC藥物。此外，蘆康沙妥珠單抗(sac-TMT)用於既往接受過內分泌治療且在晚期或轉移性階段接受過其他系統治療的不可切除的局部晚期或轉移性HR+/HER2- BC的sNDA已獲國家藥品監督管理局(NMPA)藥品審評中心(CDE)受理，並被納入優先審評審批程式。 截止目前，本公司已在中國開展9項註冊性臨床研究。默沙東已啟動15項正在進行的蘆康沙妥珠單抗(sac-TMT)作為單藥療法或聯合帕博利珠單抗或其他抗癌藥物用於多種類型癌症的全球性III期臨床研究(這些研究由默沙東申辦並主導)。 *帕博利珠單抗(可瑞達®)為美國新澤西州羅威市默克公司的附屬公司Merck Sharp & Dohme LLC (MSD)的註冊商標 關於西妥昔單抗N01(達泰萊®) 西妥昔單抗N01是公司自主研發的重組表皮生長因數受體（EGFR）人鼠嵌合單克隆抗體（mAb），用於晚期結直腸癌患者。這是國內首個通過III期臨床研究證實，在一線治療RAS野生型轉移性結直腸癌患者中，與原研西妥昔單抗注射液（愛必妥®）聯合化療方案進行頭對頭對比，且取得類似臨床結果的國產生物藥。目前，西妥昔單抗N01與FOLFOX或FOLFIRI方案聯合用於一線治療RAS基因野生型的轉移性結直腸癌患者已獲NMPA批准上市。 關於塔戈利單抗(科泰萊®) 塔戈利單抗是全球首個獲批用於一線治療鼻咽癌的PD-L1單克隆抗體。此前，中國國家藥品監督管理局（NMPA）已批准塔戈利單抗兩項適應症上市，包括聯合順鉑和吉西他濱一線治療復發或轉移性鼻咽癌患者以及單藥治療既往接受過2線及以上化療失敗的復發或轉移性鼻咽癌患者。 關於科倫博泰 四川科倫博泰生物醫藥股份有限公司(簡稱「科倫博泰生物」，股票代碼：6990.HK)是科倫藥業控股子公司，專注於創新生物技術藥物及小分子藥物的研發、生產、商業化及國際合作。公司圍繞全球和中國未滿足的臨床需求，重點佈局腫瘤、自身免疫、炎症和代謝等重大疾病領域，建設國際化藥物研發與產業化平臺，致力於成為在創新藥物領域國際領先的企業。公司目前擁有30余個重點創新藥項目，其中4個項目已獲批上市，1個專案處於NDA階段，10餘個專案正處於臨床階段。公司成功構建了享譽國際的專有ADC及新型偶聯藥物平臺OptiDC™，已有2個ADC項目獲批上市，多個ADC或新型偶聯藥物產品處於臨床或臨床前研究階段。更多資訊請訪問官網https://kelun-biotech.com/。
TAIPEI, Dec. 7, 2025 /PRNewswire/ -- Skymizer today announced that its next-generation HyperThought™ LLM Accelerator IP has been awarded "Best IP/Processor of the Yearˮ and named the "Most Promising Productˮ at the prestigious EE Awards Asia 2025, hosted by ASPENCORE at the Grand Mayfull Taipei Hotel. The dual recognition marks HyperThought as one of the most forward-looking semiconductor IP breakthroughs in the Asia-Pacific technology landscape. Now celebrating its 5th anniversary, the EE Awards Asia program honors innovations selected by engineers and industry leaders across the region. HyperThought™ stood out among hundreds of entries spanning processors, SoCs, sensors, wireless ICs, AI solutions, and test equipment—earning top distinction as the yearʼs most transformative semiconductor IP. HyperThought™: Accelerating the Future of Agentic, Multimodal SoCs Skymizerʼs HyperThought™ represents a new class of multimodal, scalable LLM accelerator IP purpose-built for the coming generation of agentic AI workflows, on-device intelligence, and edge-to-cloud hybrid applications. Unlike conventional NPUs or fixed-function ML accelerators, HyperThought is architected from the ground up for: Multimodal LLM/VLM ExecutionSupporting text, vision, speech, and sensor-based AI with unified token processing. Agentic Workflow OptimizationAccelerating the emerging class of AI agents that require real-time planning, reflection, tool-use, and memory. Scalable Edge-to-Enterprise DeploymentFrom micro-edge devices and automotive ECUs to humanoid robots, smart cameras, and industrial IoT gateways. Superior Performance-per-Watt and SRAM EfficiencyDelivering next-generation TTFT, TPS, context window, and latency performance under strict edge-power envelopes. Skymizer CMO William Wei: "HyperThought is Built for the Agentic SoC Eraˮ William Wei, Chief Marketing Officer of Skymizer, represented the company at the EE Awards Asia 2025 ceremony and emphasized the strategic significance of this win: "HyperThought™ is not just an accelerator IP — it is a foundation for the next decade of agentic intelligence. From multimodal LLMs to real-time robotic and automotive agents, the future SoC must run AI that plans, reasons, sees, acts, and interacts. HyperThought was designed precisely for this new era.ˮ Wei added that the award validates Skymizerʼs long-term bet on on-device agentic AI, predicting that LLM-centric SoCs will become the defining architecture for mobile, automotive, robotics, and edge computing. A Milestone for Skymizer and the Asia Semiconductor Ecosystem The EE Awards Asia jury highlighted HyperThought for its: Breakthrough support for multimodal transformer workloads High scalability across process nodes and SoC configurations Strong alignment with global trends in on-device LLM inference Potential to reshape AI compute in edge, robotics, and smart-device markets HyperThoughtʼs recognition as "Most Promising Productˮ places Skymizer among the leaders defining next-generation AI silicon, with strong interest from ecosystem partners in automotive, robotics, edge AI, and consumer electronics. About Skymizer Skymizer is a Taiwan-based AI semiconductor IP company specializing in LLM acceleration, compiler technology, and agentic AI system architectures. Its flagship HyperThought™ IP gives SoC manufacturers the ability to build their own AI-native processors for multimodal LLMs, autonomous agents, and edge intelligence.
SAN FRANCISCO and SUZHOU, China, Dec. 7, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that seven of its innovative products have been included in the updated 2025 National Reimbursement Drug List (NRDL). This list features a new indication of TYVYT® (sintilimab injection), and first-time inclusions of SYCUME® (teprotumumab N01 injection, a recombinant anti-IGF-1R antibody), Limertinib (EGFR TKI), Dupert® (fulzerasib, KRAS G12C inhibitor), DOVBLERON® (taletrectinib, ROS1 inhibitor), Retsevmo® (selpercatinib, RET inhibitor), and Jaypirca® (pirtobrutinib, BTK inhibitor). The updated NRDL will be officially effective from January 1, 2026. Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, stated: "We are pleased with the NRDL inclusion of our seven innovative therapies this year. These therapies cover key disease areas that pose substantial public health challenges in China—particularly oncology (including lung, liver, gastric, esophageal, gynecological cancers, and hematological malignancies) as well as cardiovascular and metabolic (CVM) diseases. Their inclusion will help broaden patients' access to and enhance their affordability of these medications, ultimately benefiting more individuals and families across the country. As a company with the mission of 'empowering patients worldwide with affordable, high-quality biopharmaceuticals', Innovent continues to invest in pioneering treatments across oncology, CVM, autoimmune and ophthalmology—areas of significant societal need. We remain committed to our patient-centered approach, leveraging our innovation and product capabilities to further improve drug affordability and accessibility, so that high-quality medicines can reach and benefit more patients and their families as soon as possible. We are proud to contribute to better care for our patients." TYVYT® (sintilimab injection) TYVYT® (sintilimab injection) is a PD-1 immunoglobulin G4 monoclonal antibody co-developed by Innovent and Eli Lilly and Company. In China, sintilimab has been approved for eight indications and two more NDAs are under review by the NMPA, including squamous non-small cell lung cancer (NSCLC), non-squamous NSCLC, liver cancer, gastric cancer, esophageal cancer, endometrial cancer and Hodgkin's lymphoma[i]. In the updated NRDL, the eighth indication of TYVYT®(sintilimab injection) is newly included, in combination with fruquintinib for the treatment of patients with advanced endometrial cancer with Mismatch Repair proficient (pMMR) tumors that have failed prior systemic therapy and are not candidates for curative surgery or radiation. This new indication addresses a critical gap in treatments available for advanced endometrial cancer patients with limited responses to traditional therapies. SYCUME® (teprotumumab N01 injection) SYCUME® (teprotumumab N01 injection) is a recombinant anti-insulin-like growth factor 1 receptor (IGF-1R) antibody developed by Innovent. SYCUME® blocks the activation of IGF-1R signaling pathway, consequently improving clinical manifestations such as proptosis, inflammation and diplopia, thus enhancing quality of life in patients with thyroid eye disease (TED)[ii]. In the updated NRDL, SYCUME®(teprotumumab N01 injection) is newly listed for moderate-to-severe thyroid eye disease. SYCUME®(teprotumumab N01 injection) is China's first approved IGF-1R antibody drug, and this groundbreaking non-invasive therapy redefines the standard of care and serves the unmet needs for thyroid eye disease over past 70 years in China. The NRDL inclusion will bring this world-class novel treatment option to Chinese patients with thyroid eye disease and significantly enhance patient accessibility and affordability. Limertinib Limertinib is a third-generation EGFR TKI in collaboration with ASK Pharm, and Innovent holds exclusive commercialization rights in Mainland China.[iii] In the updated NRDL, limertinib is newly listed for: 1) the treatment of adult patients with locally advanced or metastatic EGFR T790M-mutated non-small cell lung cancer (NSCLC), who have previously experienced disease progression during or after treatment with EGFR TKI; and 2) the first-line treatment of adult patients with locally advanced or metastatic NSCLC carrying EGFR exon 19 deletions or exon 21 L858R mutations. Limertinib incorporates a unique naphthylamine group structure, which endows it with enhanced lipophilicity. This property ensures effective drug penetrate across the blood-brain barrier (BBB), thereby significantly reducing the risk of disease progression—specifically, the risk of disease progression in patients with brain metastases and the risk of intracranial disease progression. The NRDL inclusion of limertinib will provide a more effective treatment option for NSCLC patients with EGFR mutations. Dupert® (fulzerasib) Dupert® (fulzerasib) is a novel KRAS G12C inhibitor in collaboration with GenFleet Therapeutics, and Innovent holds exclusive development and commercialization rights in Greater China.[iv] In the updated NRDL, Dupert®(fulzerasib) is newly listed for the treatment of advanced NSCLC adult patients harboring KRAS G12C mutation who have received at least one systemic therapy. The NRDL inclusion of Dupert®(fulzerasib) will provide a novel targeted therapy benefiting NSCLC patients harboring KRAS G12C mutation. DOVBLERON® (taletrectinib) DOVBLERON® (taletrectinib) is a novel next-generation ROS1 TKI in collaboration with Nuvation Bio China, a Nuvation Bio (NYSE: NUVB) Company, and Innovent holds exclusive commercialization rights in Greater China.[v] In the updated NRDL, DOVBLERON® (taletrectinib) is newly listed for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC. The NRDL inclusion of DOVBLERON® (taletrectinib) will provide a potentially best-in-class therapy benefiting patients with locally advanced ROS1-positive NSCLC. Retsevmo® (selpercatinib) Retsevmo® (selpercatinib) is a selective and potent rearranged during transfection (RET) kinase inhibitor developed by Eli Lilly and Company and solely commercialized in Mainland China by Innovent.[vi] In the updated NRDL, Retsevmo® (selpercatinib) is newly listed for the treatment of: 1) adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a RET gene fusion, 2) adult and pediatric patients 12 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation who require systemic therapy, and 3) adult and pediatric patients 12 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion who require systemic therapy and who are radioactive iodine-refractory. Retsevmo® (selpercatinib) is the first RET inhibitor approved globally and its NRDL inclusion will bring an innovative therapy for NSCLC and thyroid cancer patients with a RET alteration. Jaypirca® (pirtobrutinib) Jaypirca® (pirtobrutinib) is a non-covalent (reversible) BTK inhibitor developed by Eli Lilly and Company and solely commercialized in Mainland China by Innovent. Jaypirca® (pirtobrutinib) is the first and only non-covalent (reversible) BTK inhibitor approved in the world.[vii] In the updated NRDL, Jaypirca® is newly listed for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after at least two types of systemic therapy, including a BTK inhibitor. Its NRDL inclusion will benefit heavily-treated MCL patients that previously received the treatment of a BTK inhibitor, addressing their unmet needs and further enhancing Jaypirca's affordability for those patients. About Innovent Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 17 products in the market. It has 1 new drug applications under regulatory review, 4 assets in Phase 3 or pivotal clinical trials and 15 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center. Guided by the motto, "Start with Integrity, Succeed through Action" Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn. Statements: Innovent does not recommend the use of any unapproved drug (s)/indication (s). Ramucirumab（Cyramza）, Selpercatinib (Retsevmo) and Pirtobrutinib (Jaypirca) were developed by Eli Lilly and Company. Forward-Looking Statements This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent, are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly. These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions. The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect. [i] TYVYT® (sintilimab injection) Product Insert [ii] SYCUME® (teprotumumab N01 injection) Product Insert [iii] Limertinib Product Insert [iv] Dupert® (fulzerasib) Product Insert [v] DOVBLERON® (taletrectinib) Product Insert [vi] Retsevmo® (selpercatinib) Product Insert [vii] Jaypirca® (pirtobrutinib) Product Insert
韓國首爾2025年12月7日 /美通社/ -- DWMaterials以其新一代電磁分離器技術作為增長基石，加速向二次電池和先進材料行業擴張。 憑借在熱交換器和反應器工程領域超過30年的技術積累，該公司正在從傳統設備製造邁向新賽道，鞏固其作為助力客戶提升質量競爭力的技術合作夥伴的地位。 在二次電池領域，異物去除技術是直接關係到電芯質量和安全的關鍵因素。憑借其專有的高純度消磁與分離技術，DWMaterials逐漸成為新一代電池生產線的重要設備供應商。 公司發言人表示：「我們不僅僅是設備供應商，更是值得信賴的合作夥伴，可以保障客戶的可靠性和質量。DWMaterials將繼續擴大其在全球材料行業的業務版圖。」
SEOUL, South Korea, Dec. 7, 2025 /PRNewswire/ -- DWMaterials is accelerating its expansion into the secondary battery and advanced materials industries, leveraging its next-generation electromagnetic separator technology as a foundation for growth. With over 30 years of accumulated expertise in heat exchanger and reactor engineering, the company is evolving beyond traditional equipment manufacturing to strengthen its position as a technology partner that enhances customers' quality competitiveness. In the secondary battery sector, foreign substance removal technology is a crucial factor directly linked to cell quality and safety. Equipped with its proprietary high-purity demagnetization and separation technology, DWMaterials is emerging as a key equipment supplier for next-generation battery production lines. A company representative stated, "We are not merely an equipment supplier, but a trusted partner that guarantees our customers' reliability and quality," adding, "DWMaterials will continue to expand its footprint across the global materials industry."
A12 藝術空間
IR
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
